Home
Companies
Catalysts
Deep Dives
Elahere
mirvetuximab soravtansine
APPROVED
Drug Profile
Modality
ADC
Route
IV
Therapy Area
Oncology
Launch
2022-11-14
US LOE
2035-11-14
Peak Sales Est
$2000M
Formulations
[{"id":"elahere-iv","route":"IV","setting":"INFUSION_CENTER","frequency":"Every 3 weeks","is_primary
Companies
ABBV
(ORIGINATOR)
100%
Mechanism: FRα-targeting ADC
Expert:
Antibody-drug conjugate targeting folate receptor alpha with DM4 maytansinoid payload, inducing mitotic arrest and apoptosis.
Everyday:
A targeted drug that delivers chemotherapy directly to ovarian cancer cells.
Targets: ["FOLR1"]
Revenue History
Period
Revenue ($M)
2024
$481M
2025
$690M
Q4 2025
$195M
Programs (1)
Indication
Stage
Key Study
Regional Status
FRα+ OvCa
APPROVED
SORAYA, MIRASOL
[{"stage":"APPROVED","region":"US","approval_date":"2022-11-14"}]
Notes
First FRα-targeting ADC for platinum-resistant ovarian cancer. Acquired from ImmunoGen. 2025 revenue $690M (+43% YoY). Growing rapidly in FRα-high patients.
Data from Supabase · Updated 2026-03-24